Oncometabolites: A new paradigm for oncology, metabolism, and the clinical laboratory

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Background: Pediatric clinical laboratories commonly measure tricarboxylic acid cycle intermediates for screening, diagnosis, and monitoring of specific inborn errors of metabolism, such as organic acidurias. In the past decade, the same tricarboxylic acid cycle metabolites have been implicated and studied in cancer. The accumulation of these metabolites in certain cancers not only serves as a biomarker but also directly contributes to cellular transformation, therefore earning them the designation of oncometabolites. Content: D-2-hydroxyglutarate, L-2-hydroxyglutarate, succinate, and fumarate are the currently recognized oncometabolites. They are structurally similar and share metabolic proximity in the tricarboxylic acid cycle. As a result, they promote tumorigenesis in cancer cells through similar mechanisms. This review summarizes the currently understood common and distinct biological features of these compounds. In addition, we will review the current laboratory methodologies that can be used to quantify these metabolites and their downstream targets. Summary: Oncometabolites play an important role in cancer biology. The metabolic pathways that lead to the production of oncometabolites and the downstream signaling pathways that are activated by oncometabolites represent potential therapeutic targets. Clinical laboratories have a critical role to play in the management of oncometabolite-associated cancers through development and validation of sensitive and specific assays that measure oncometabolites and their downstream effectors. These assays can be used as screening tools and for follow-up to measure response to treatment, as well as to detect minimal residual disease and recurrence.

Original languageEnglish (US)
Pages (from-to)1812-1820
Number of pages9
JournalClinical Chemistry
Volume63
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Clinical laboratories
Oncology
Medical Oncology
Metabolites
Metabolism
Citric Acid Cycle
Assays
Screening
Neoplasms
Fumarates
Pediatrics
Succinic Acid
Biomarkers
Inborn Errors Metabolism
Cells
Residual Neoplasm
Metabolic Networks and Pathways
Monitoring
Carcinogenesis
Recurrence

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Oncometabolites : A new paradigm for oncology, metabolism, and the clinical laboratory. / Collins, Rebecca R.J.; Patel, Khushbu; Putnam, William C.; Kapur, Payal; Rakheja, Dinesh.

In: Clinical Chemistry, Vol. 63, No. 12, 01.12.2017, p. 1812-1820.

Research output: Contribution to journalReview article

@article{9d1c25f4102544049ac71d8136814cc2,
title = "Oncometabolites: A new paradigm for oncology, metabolism, and the clinical laboratory",
abstract = "Background: Pediatric clinical laboratories commonly measure tricarboxylic acid cycle intermediates for screening, diagnosis, and monitoring of specific inborn errors of metabolism, such as organic acidurias. In the past decade, the same tricarboxylic acid cycle metabolites have been implicated and studied in cancer. The accumulation of these metabolites in certain cancers not only serves as a biomarker but also directly contributes to cellular transformation, therefore earning them the designation of oncometabolites. Content: D-2-hydroxyglutarate, L-2-hydroxyglutarate, succinate, and fumarate are the currently recognized oncometabolites. They are structurally similar and share metabolic proximity in the tricarboxylic acid cycle. As a result, they promote tumorigenesis in cancer cells through similar mechanisms. This review summarizes the currently understood common and distinct biological features of these compounds. In addition, we will review the current laboratory methodologies that can be used to quantify these metabolites and their downstream targets. Summary: Oncometabolites play an important role in cancer biology. The metabolic pathways that lead to the production of oncometabolites and the downstream signaling pathways that are activated by oncometabolites represent potential therapeutic targets. Clinical laboratories have a critical role to play in the management of oncometabolite-associated cancers through development and validation of sensitive and specific assays that measure oncometabolites and their downstream effectors. These assays can be used as screening tools and for follow-up to measure response to treatment, as well as to detect minimal residual disease and recurrence.",
author = "Collins, {Rebecca R.J.} and Khushbu Patel and Putnam, {William C.} and Payal Kapur and Dinesh Rakheja",
year = "2017",
month = "12",
day = "1",
doi = "10.1373/clinchem.2016.267666",
language = "English (US)",
volume = "63",
pages = "1812--1820",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "12",

}

TY - JOUR

T1 - Oncometabolites

T2 - A new paradigm for oncology, metabolism, and the clinical laboratory

AU - Collins, Rebecca R.J.

AU - Patel, Khushbu

AU - Putnam, William C.

AU - Kapur, Payal

AU - Rakheja, Dinesh

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background: Pediatric clinical laboratories commonly measure tricarboxylic acid cycle intermediates for screening, diagnosis, and monitoring of specific inborn errors of metabolism, such as organic acidurias. In the past decade, the same tricarboxylic acid cycle metabolites have been implicated and studied in cancer. The accumulation of these metabolites in certain cancers not only serves as a biomarker but also directly contributes to cellular transformation, therefore earning them the designation of oncometabolites. Content: D-2-hydroxyglutarate, L-2-hydroxyglutarate, succinate, and fumarate are the currently recognized oncometabolites. They are structurally similar and share metabolic proximity in the tricarboxylic acid cycle. As a result, they promote tumorigenesis in cancer cells through similar mechanisms. This review summarizes the currently understood common and distinct biological features of these compounds. In addition, we will review the current laboratory methodologies that can be used to quantify these metabolites and their downstream targets. Summary: Oncometabolites play an important role in cancer biology. The metabolic pathways that lead to the production of oncometabolites and the downstream signaling pathways that are activated by oncometabolites represent potential therapeutic targets. Clinical laboratories have a critical role to play in the management of oncometabolite-associated cancers through development and validation of sensitive and specific assays that measure oncometabolites and their downstream effectors. These assays can be used as screening tools and for follow-up to measure response to treatment, as well as to detect minimal residual disease and recurrence.

AB - Background: Pediatric clinical laboratories commonly measure tricarboxylic acid cycle intermediates for screening, diagnosis, and monitoring of specific inborn errors of metabolism, such as organic acidurias. In the past decade, the same tricarboxylic acid cycle metabolites have been implicated and studied in cancer. The accumulation of these metabolites in certain cancers not only serves as a biomarker but also directly contributes to cellular transformation, therefore earning them the designation of oncometabolites. Content: D-2-hydroxyglutarate, L-2-hydroxyglutarate, succinate, and fumarate are the currently recognized oncometabolites. They are structurally similar and share metabolic proximity in the tricarboxylic acid cycle. As a result, they promote tumorigenesis in cancer cells through similar mechanisms. This review summarizes the currently understood common and distinct biological features of these compounds. In addition, we will review the current laboratory methodologies that can be used to quantify these metabolites and their downstream targets. Summary: Oncometabolites play an important role in cancer biology. The metabolic pathways that lead to the production of oncometabolites and the downstream signaling pathways that are activated by oncometabolites represent potential therapeutic targets. Clinical laboratories have a critical role to play in the management of oncometabolite-associated cancers through development and validation of sensitive and specific assays that measure oncometabolites and their downstream effectors. These assays can be used as screening tools and for follow-up to measure response to treatment, as well as to detect minimal residual disease and recurrence.

UR - http://www.scopus.com/inward/record.url?scp=85036645850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036645850&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2016.267666

DO - 10.1373/clinchem.2016.267666

M3 - Review article

C2 - 29038145

AN - SCOPUS:85036645850

VL - 63

SP - 1812

EP - 1820

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 12

ER -